Fight for Sight has announced funding for research into the role of a protein in the development of age-related macular degeneration (AMD).
Researchers from the University of Manchester will aim to investigate the impact of Inter-alpha-inhibitor Heavy Chain 3 (ITIH3) on membranes from donated eyes, as it has been found to contribute to controlling immune responses, inflammation and cell functions in other parts of the body.
Dr Simon Clark from the University of Manchester said: ‘ITIH3 has never been known to be present in the back of the eye before. The fact that we know it regulates inflammation and cellular functions in other parts of the body opens up possibilities for its role in the eye. We’re very optimistic it will play a significant role in our quest to find a therapy for AMD.’